These data suggest that the true prevalence of hypercalcemia in ovarian cancer, i.e., of an albumin-corrected serum calcium >2.6 mmol/L, likely is higher than the estimate of 5% reported in the literature (which was based on uncorrected serum calcium) [[20]]. This evidence concerns the gene ALB and hypercalcemia disease.